CTT Pharma Advances Manufacturing and Regulatory Plans for Patented Drug Delivery Technology

CTT Pharma CEO Ryan Khouri has issued a letter to shareholders detailing the company's progress toward commercializing its patented micelle thin-film technology for oral drug delivery. The company is preparing to file an S-1 registration statement to become an SEC reporting company, which is expected to occur by the end of 2025 or early in the first quarter of 2026. This transition aims to enhance transparency and potentially attract a broader base of investors. The capital accessed through an equity line of credit will be directed toward manufacturing the company's technology.

The immediate commercial focus for 2026 is on manufacturing micelle-encapsulated vitamins, bioactive supplement strips, and nicotine oral strips. CTT Pharma is currently in the process of locating a manufacturing facility, with plans to identify a building in the first quarter of 2026 and subsequently acquire necessary production equipment. To support these efforts, the company is strengthening its team by adding regulatory experts to navigate approval processes in North America and an individual with extensive experience in bringing commercial products to market.

A significant development is the acceptance of a scholarly review manuscript for publication on December 15, 2025. The paper, submitted by CTT scientist Dr. Katharine Cole and founder Dr. Pankaj Modi, provides a comprehensive review of current research in micelle and oral dissolvable strip technology. This publication is expected to increase visibility and understanding of the scientific principles behind CTT's platform, potentially engaging shareholders, prospective partners, and the scientific community. The company plans to distribute the publication to shareholders via a news release after its publication date.

CTT Pharma's partnership with Johns Hopkins University, part of an NIH grant to develop the technology as a smoking cessation alternative, awaits a funding decision for clinical trials. The company notes that its manufacturing and commercialization plans are independent of the timing of this NIH decision. Additionally, CEO Khouri emphasized ongoing efforts to strengthen the company's patent portfolio and announced plans for a conference call in the first quarter to discuss progress and upcoming initiatives.

The advancements outlined by CTT Pharma could have notable implications for the drug delivery industry. The company's focus on micelle thin-film technology aims to offer better, faster, and more convenient oral drug delivery options, potentially improving patient adherence and expanding treatment modalities. For investors, the move to SEC reporting status may increase market credibility and liquidity, while the scientific publication and regulatory hiring signal a commitment to evidence-based development and compliance. The planned manufacturing of nicotine oral strips also taps into the growing market for smoking cessation products, aligning with public health initiatives. As CTT Pharma expands its team and advances toward production, these steps position the company to potentially capture value in a competitive sector driven by innovation in drug delivery systems.